Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nuvation Bio Inc (NY: NUVB )

2.300 +0.090 (+4.07%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nuvation Bio Inc

< Previous 1 2 3 4 Next >
Fastenal Posts Upbeat Earnings, Joins Wells Fargo, JPMorgan And Other Big Stocks Moving Higher On Friday
Via Benzinga
Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer
From Nuvation Bio Inc.
Via Business Wire
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
From Nuvation Bio Inc.
Via Business Wire
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Nuvation Bio to Present at the Cantor Global Healthcare Conference
From Nuvation Bio
Via Business Wire
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage... 
Via Benzinga
Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib
From Nuvation Bio Inc.
Via Business Wire
NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
Via Benzinga
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
From Nuvation Bio Inc.
Via Business Wire
NUVB Stock Earnings: Nuvation Bio Beats EPS for Q1 2024
NUVB stock results show that Nuvation Bio beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Nuvation Bio Inc.
Via Business Wire
Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday
Via Benzinga
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
From Nuvation Bio Inc.
Via Business Wire
ProfoundBio Discovers The Joys Of Having A Wealthy Owner
Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a... 
Via Benzinga
Intel, XPeng And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq futures falling by around 0.2% on Wednesday. 
Via Benzinga
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal
South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770 million. The company acquiring the asset asked to remain anonymous because... 
Via Talk Markets
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
From Nuvation Bio Inc.
Via Business Wire
Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of LuxUrban Hotels Inc. (NASDAQ: LUXH) fell sharply during Wednesday’s session after the company issued preliminary fourth-quarter revenue outlook below estimates. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Netflix To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Why MariaDB Shares Are Trading Higher By Around 100%; Here Are 20 Stocks Moving Premarket
Shares of MariaDB plc (NYSE: MRDB) rose sharply in today’s pre-market trading after Progress Software (NASDAQ: PRGS) announced that it is possibly considering an offer for the company. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers for Wednesday morning as we check out all of the hottest news! 
Via InvestorPlace
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Tesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.